Influenza antigen delivery vectors and constructs

Abstract

The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.

Claims

1. A vector-antigen construct comprising: an antigenic influenza peptide sequence covalently attached to a vector, wherein the vector is of structure C.sub.mX.sub.nC.sub.yH.sub.x-(Sp)-R, wherein m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3 to 30, Sp is an optional chemical spacer moiety, R is the antigenic influenza peptide and X is selected from a fluorine, chlorine, bromine or iodine, and wherein the antigenic influenza peptide is up to 40 amino acids in length and comprises any one of SEQ ID NOs: 1 to 65.

2. The vector-antigen construct of claim 1, wherein the antigenic influenza peptide comprises an amino acid sequence of any one of SEQ ID NOs: 1, 4, 17, 18, 32 or 35.

3. The vector-antigen construct of claim 1, wherein the vector is of structure C.sub.mF.sub.nC.sub.yH.sub.x-(Sp)-R, wherein m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3 to 30, Sp is an optional chemical spacer moiety and R is the antigenic influenza peptide.

4. The vector-antigen construct of claim 1, wherein the vector comprises structure ##STR00004## where Sp is an optional chemical spacer moiety and R is the antigenic influenza peptide.

5. A pharmaceutical composition for intracellular delivery of an antigen, the composition comprising an antigenic influenza peptide sequence covalently attached to a vector, wherein the vector is of structure C.sub.mX.sub.nC.sub.yH.sub.x-(Sp)-R, wherein m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3 to 30, Sp is an optional chemical spacer moiety, R is the antigenic influenza peptide and X is selected from a fluorine, chlorine, bromine or iodine, and wherein the antigenic influenza peptide is up to 40 amino acids in length and comprises any one of SEQ ID NOs: 1 to 65.

6. The composition of claim 5, wherein the vector is of structure C.sub.mF.sub.nC.sub.yH.sub.x-(Sp)-R, wherein m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3 to 30, Sp is an optional chemical spacer moiety and R is the antigenic influenza peptide.

7. The composition of claim 5, wherein the vector comprises structure ##STR00005## where Sp is an optional chemical spacer moiety and R is the antigenic influenza peptide.

8. The composition of claim 5, wherein the composition comprises from 2 to 20 of the antigenic influenza peptide sequences each covalently attached to a vector.

9. The composition of claim 5, wherein the composition comprises 5, 6, 7, or 8 of the antigenic influenza peptide sequences each covalently attached to a vector.

10. The composition of claim 5, further comprising one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.

11. The composition of claim 5, formulated for parenteral, oral, ocular, rectal, nasal, transdermal, topical or vaginal administration.

12. The composition of claim 5, wherein the composition is in a form of a liquid, emulsion, solid, aerosol or gas.

13. A method of stimulating an immune response, comprising administering the composition of claim 5 to an animal.

14. The method of claim 13, wherein the animal is a mammal, a bird or a human.

15. A method of preparing a prophylactic or therapeutic pharmaceutical composition comprising combining the composition of claim 5, with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The foregoing aspects and embodiments of the invention may be more fully understood by reference to the following detailed description and claims.

(2) FIG. 1 shows a comparison of the immunogenicity of a multivalent fluoropeptide vaccine versus its native peptide equivalent in BALB/c and CBF6 mice, after prime or prime-boost, assessed by ex vivo IFN-? ELIspot assay.

(3) FIG. 2 shows a comparison of the immunogenicity of a multivalent fluoropeptide vaccine versus its native peptide equivalent in BALB/c and CBF6 mice, after prime or prime-boost, assessed by ex vivo IFN-? ELIspot assay.

(4) FIG. 3 shows a comparison of individual peptide immunogenicity of fluoropeptides verses native peptides in BALB/c and CBF6 mice after prime or prime-boost assessed by ex vivo IFN-? ELISpot.

(5) FIG. 4 shows a comparison of the immunogenicity of a multivalent fluoropeptide vaccine versus the native peptide equivalent in BALB/c and CBF6 mice after prime-boost immunization, assessed by cytokine profiles.

(6) FIG. 5 is a graph showing that both CD4+ T cells and CD8+ T cells are stimulated by the fluoropeptide vaccine in BALB/c mice.

(7) FIG. 6 shows a comparison of the immunogenicity of a multivalent fluoropeptide vaccine versus vaccine emulsified in CFA in BALB/c mice after a single immunization; assessment of cytokine profiles.

(8) FIG. 7 shows a comparison of subcutaneous versus intradermal routes of fluoropeptide vaccine administration in BALB/c mice after a single immunization: ex vivo IFN-? ELISpot assay.

DETAILED DESCRIPTION

(9) Over the decades numerous delivery methods have been evaluated, including vectors such as Penetratin, TAT and its derivatives, DNA, viral vectors, virosomes and liposomes. However, these systems either elicit very weak CTL responses, fail to generate a booster amplification on memory responses, have associated toxicity issues or are complicated and expensive to manufacture at the commercial scale. There is therefore a recognised need for improved vectors to direct the intracellular delivery of antigens in the development of vaccines and drugs intended to elicit a cellular immune response. A vector in the context of immunotherapeutics or vaccines is any agent capable of transporting or directing an antigen to immune responsive cells in a host.

(10) The present invention seeks to overcome the problem of delivering influenza antigens to immune responsive cells by using a fluorocarbon vector in order to enhance their immunogenicity. The fluorocarbon vector may comprise one or more chains derived from perfluorocarbon or mixed fluorocarbon/hydrocarbon radicals, and may be saturated or unsaturated, each chain having from 3 to 30 carbon atoms.

(11) Fluorinated surfactants have low critical micelle concentrations and thus self-organise into multimolecular micelle structures at a low concentrations. This physicochemical property is related to the strong hydrophobic interactions and low Van der Waal's interactions associated with fluorinated chains which dramatically increase the tendency of fluorinated amphiphiles to self-assemble in water and to collect at interfaces. The formation of such structures facilitates their endocytic uptake by cells, to for example antigen-presenting cells (Reichel F. et al. J. Am. Chem. Soc. 1999, 121, 7989-7997). Furthermore haemolytic activity is strongly reduced and often suppressed when fluorinated chains are introduced into a surfactant (Riess et al. Adv. Mater. 1991, 3, 249-251) thereby leading to a reduction in cellular toxicity.

(12) In order to link the vector to the antigen through a covalent linkage, a reactive group, or ligand, is incorporated as a component of the vector, for example CO, NH, S, O or any other suitable group is included; the use of such ligands for achieving covalent linkages are well-known in the art. The reactive group may be located at any position on the fluorocarbon molecule.

(13) Coupling of the fluorocarbon vector to the antigen may be achieved through functional groups such as OH, SH, COOH, NH.sub.2 naturally present or introduced onto any site of the antigen. Suitable links may contain a nitrogen, oxygen or sulphur atom, in either linear or cyclic form. Examples of the bonds formed by ligation may include oxime, hydrazone, disulphide or triazole or any suitable covalent bond. In particular, the fluorocarbon moiety could be introduced through a thioester bond to increase the immunogenicity of the peptide (Beekman et al. Synthetic peptide vaccines: palmitoylation of peptide antigens by a thioester bond increases immunogenicity. J. Peptide Res. 1997, 50, 357-364). Optionally, a spacer element (peptidic, pseudopeptidic or non-peptidic) may be incorporated to permit cleavage of the antigen from the fluorocarbon element for processing within the antigen-presenting cell and to optimise antigen presentation, as previously shown for lipopeptides (Verheul et al. Monopalmitic acid-peptide conjugates induce cytotoxic T cell responses against malarial epitopes: importance of spacer amino acids, Journal of Immunological Methods 1995, volume 182, pp 219-226).

(14) In a first aspect, the present invention provides a fluorocarbon vector-antigen construct having a chemical structure C.sub.mF.sub.n-C.sub.yH.sub.x-(Sp)-R or derivatives thereof, where m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3-30 and Sp is an optional chemical spacer moiety and R is an antigen derived from the influenza virus.

(15) In the context of the present invention derivatives refers to relatively minor modifications of the fluorocarbon compound such that the compound is still capable of delivering the antigen as described herein. Thus, for example, a number of the fluorine moieties can be replaced with other halogen moieties such as chlorine (CO, if) bromine (Br) or iodine (I). In addition it is possible to replace a number of the fluorine moieties with methyl groups and still retain the properties of the molecule as discussed herein.

(16) In a particular example of the above formula the vector may be 2H, 2H, 3H, 3H-perfluoroundecanoic acid of the following formula:

(17) ##STR00002##

(18) Thus in a second aspect the invention provides a fluorocarbon vector-antigen construct of structure

(19) ##STR00003##
where Sp is an optional chemical spacer moiety and R is an antigen derived from the influenza virus.

(20) As used herein the term antigen refers to a molecule having the ability to be recognized by immunological receptors such as T cell receptor (TCR) or B cell receptor (BCR or antibody). Antigens may be proteins, protein subunits, peptides, carbohydrates, lipid or combinations thereof, natural or non-natural, provided they present at least one epitope, for example a T cell and/or a B cell epitope.

(21) Such antigens may be derived by purification from the native protein or produced by recombinant technology or by chemical synthesis. Methods for the preparation of antigens are well-known in the art. Furthermore, antigens also include DNA or oligonucleotide encoding an antigenic peptide or protein.

(22) The antigen associated with the vector may be any influenza antigen capable of inducing an immune response in an animal, including humans. Preferably the immune response will have a beneficial effect in the host.

(23) The influenza antigen may contain one or more T cell epitopes or one or more B cell epitopes or combinations of T and B cell epitopes.

(24) The T cell epitopes may be MHC class I or class II restricted.

(25) As used herein the term epitope includes: (i) CD4+ T cell epitopes which are peptidic sequences containing an MHC class II binding motif and having the ability to be presented at the surface of antigen presenting cells by MHC class II molecules, and (ii) CD8+ T cell epitopes which are peptidic sequences containing an MHC class I binding motifs and having the ability to be presented by MHC class I molecules at the cell surface, and (iii) B cell epitopes which are peptidic sequences having a binding affinity for a B cell receptor.

(26) The antigen may comprise one or more epitopes from an influenza type A protein, an influenza type B protein or an influenza type C protein. Examples of the influenza virus proteins, from both the influenza A and B types, include: haemagglutinin, neuraminidase, matrix (M1) protein, M2, nucleoprotein (NP), PA, PB1, PB2, NS1 or NS2 in any such combination.

(27) Thus in a further aspect, the present invention provides a vector-antigen construct where the influenza virus antigen is a protein, protein subunit, peptide, carbohydrate or lipid or combinations thereof. For the construct to be immunologically active the antigen must comprise one or more epitopes. Preferably the antigen is a peptide sequence derived from the influenza virus. Peptides or proteins of the invention preferably contain a sequence of at least seven, more preferably between 9 and 100 amino-acids and most preferably between around 15 to 40 amino acids. Preferably, the amino acid sequence of the epitope(s) bearing peptide is selected to enhance the solubility of the molecule in aqueous solvents. Furthermore, the terminus of the peptide which does not conjugate to the vector may be altered to promote solubility of the construct via the formation of multi-molecular structures such as micelles, lamellae, tubules or liposomes. For example, a positively charged amino acid could be added to the peptide in order to promote the spontaneous assembly of micelles. Either the N-terminus or the C-terminus of the peptide can be coupled to the vector to create the construct. To facilitate large scale synthesis of the construct, the N- or C-terminal amino acid residues of the peptide can be modified. When the desired peptide is particularly sensitive to cleavage by peptidases, the normal peptide bond can be replaced by a non-cleavable peptide mimetic; such bonds and methods of synthesis are well known in the art.

(28) Non-standard, non-natural amino-acids can also be incorporated in peptide sequences provided that they do not interfere with the ability of the peptide to interact with MHC molecules and remain cross-reactive with T cells recognizing the natural sequences. Non-natural amino-acids can be used to improve peptide resistance to protease or chemical stability. Examples of non-natural amino acids include the D-amino-acids and cysteine modifications.

(29) More than one antigen may be linked together prior to attachment to the fluorocarbon vector. One such example is the use of fusion peptides where a promiscuous T helper epitope can be covalently linked to one or multiple CTL epitopes or one or multiple B cell epitope which can be a peptide, a carbohydrate, or a nucleic acid. As an example, the promiscuous T helper epitope could be the PADRE peptide, tetanus toxoid peptide (830-843) or influenza haemagglutinin, HA (307-319). Alternatively, the peptide sequence may contain two or more epitopes, which may be overlapping thereby creating a cluster of densely packed multi-specific epitopes, or contiguous, or separated by a stretch of amino acids.

(30) Thus in a further aspect, the present invention provides a vector-antigen construct where R is more than one epitope or antigen linked together. Epitopes may also be linear overlapping thereby creating a cluster of densely packed multi-specific epitopes.

(31) Due to the strong non-covalent molecular interactions characteristic to fluorocarbons, the antigen may also be non-covalently associated with the vector and still achieve the aim of being favorably taken up by antigen-presenting cells.

(32) Thus in a further aspect, the present invention provides a vector/antigen construct where the antigen is non-covalently associated with the fluorocarbon vector.

(33) Antigens bearing one or more B-cell epitopes may also be attached to the fluorocarbon vector, either with or without one or more T-cell epitopes. B cell epitopes can be predicted using in silico approaches (Bublil et al. Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm. Proteins. 2007 Jul. 1; 68(1):294-304. Greenbaum et al. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools J Mol Recognit. 2007 March-April; 20(2):75-82).

(34) The present invention also provides vaccines and immunotherapeutics comprising one or more fluorocarbon vector-antigen constructs. Multi-component products of this type are desirable since they are likely to be more effective in eliciting appropriate immune responses in a greater number of individuals. Due to extreme HLA polymorphism in humans, it is unlikely that a single fluoropeptide will induce a multiepitopic immune response in a high percentage of a given population. Therefore, in order for a vaccine product to be effective across a population a number of fluoropeptides may be necessary in the vaccine formulation in order to provide broad coverage. Moreover, the optimal formulation of an influenza vaccine or immunotherapeutic may comprise a number of different peptide sequences derived from different influenza virus antigens. In this case the peptides may be linked together attached to a single fluorocarbon vector or each peptide antigen could be bound to a dedicated vector.

(35) A multi-component product may contain one or more vector-antigen constructs, more preferably 2 to about 20, more preferably 3 to about 10. In particular embodiments the multi component vaccine may contain 5, 6, 7 or 8 eight constructs. This ensures that a multi-epitopic T-cell response is generated with a broad population coverage (i.e., addresses HLA diversity). For example, a formulation of multiple fluoropeptides may be composed of influenza A derived peptides alone, influenza B derived peptides alone or influenza C derived peptides alone or combinations of influenza types, most preferably influenza A and B.

(36) In one embodiment the product comprises at least two vector-antigen constructs, the first construct comprising the influenza peptide sequence:

(37) TABLE-US-00004 (SEQIDNO:1) HMAIIKKYTSGRQEKNPSLRMKWMMAMKYPITADK
and the second construct comprising the influenza peptide sequence:

(38) TABLE-US-00005 (SEQIDNO:17) YITRNQPEWFRNVLSIAPIMFSNKMARLGKGYMFE

(39) In a further embodiment the product comprises 8 vector-antigen constructs which comprise the following influenza peptide sequences:

(40) TABLE-US-00006 Construct1- (SEQIDNO:1) HMAIIKKYTSGRQEKNPSLRMKWMMAMKYPITADK Construct2- (SEQIDNO:4) VAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQG Construct3- (SEQIDNO:17) YITRNQPEWFRNVLSIAPIMFSNKMARLGKGYMFE Construct4- (SEQIDNO:18) APIMFSNKMARLGKGYMFESKXMKLRTQIPAEMLA,where XcanbeRorS Construct5- (SEQIDNO:19) SPGMMMGMFNMLSTVLGVSILNLGQKKYTKTTY Construct6- (SEQIDNO:20) KKKSYINKTGTFEFTSFFYRYGFVANFSMELPSFG Construct7- (SEQIDNO:32) DQVRESRNPGNAEIEDLIFLARSALILRGSVAHKS Construct8- (SEQIDNO:35) DLEALMEWLKTRPILSPLTKGILGFVFTLTVPSER

(41) Alternatively, multiple epitopes may be incorporated into a formulation in order to confer immunity against a range of pathogens, one of which is the influenza virus. For example a respiratory infection vaccine may contain antigens from influenza virus and respiratory syncytial virus.

(42) Compositions of the invention comprise fluorocarbon vectors associated to antigens optionally together with one or more pharmaceutically acceptable carriers and/or adjuvants. Such adjuvants and/or pharmaceutically acceptable carriers, would be capable of further potentiating the immune response both in terms of magnitude and/or cytokine profile, and may include, but are not limited to: (1) natural or synthetically derived refinements of natural components of bacteria such as Freund's adjuvant & its derivatives, muramyldipeptide (MDP) derivatives, CpG, monophosphoryl lipid A; (2) other known adjuvant or potentiating agents such as saponins, aluminium salts and cytokines; (3) methods of formulating antigens with or without extraneous adjuvants (see 1 & 2 above) such as oil in water adjuvants, water-in-oil adjuvants, immunostimulating complex (ISCOMs), liposomes, formulated nano and micro-particles; (4) bacterial toxins and toxoids; and (5) other useful adjuvants well-known to one skilled in the art.

(43) The choice of carrier if required is frequently a function of the route of delivery of the composition. Within this invention, compositions may be formulated for any suitable route and means of administration. Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, ocular, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, transdermal) administration.

(44) The formulation may be administered in any suitable form, for example as a liquid, solid, aerosol, or gas. For example, oral formulations may take the form of emulsions, syrups or solutions or tablets or capsules, which may be enterically coated to protect the active component from degradation in the stomach. Nasal formulations may be sprays or solutions. Transdermal formulations may be adapted for their particular delivery system and may comprise patches. Formulations for injection may be solutions or suspensions in distilled water or another pharmaceutically acceptable solvent or suspending agent.

(45) Thus in a further aspect, the present invention provides a prophylactic or therapeutic formulation comprising the vector-antigen construct(s) with or without a suitable carrier and/or adjuvant.

(46) The appropriate dosage of the vaccine or immunotherapeutic to be administered to a patient will be determined in the clinic. However, as a guide, a suitable human dose, which may be dependent upon the preferred route of administration, may be from 1 to 1000 ?g. Multiple doses may be required to achieve an immunological or clinical effect, which, if required, will be typically administered between 2 to 12 weeks apart. Where boosting of the immune response over longer periods is required, repeat doses 1 month to 5 years apart may be applied.

(47) The formulation may combine the vector-antigen construct with another active component to effect the administration of more than one vaccine or drug. A synergistic effect may also be observed through the co-administration of the two or more actives.

(48) A vaccine formulation of the invention, comprising one or more fluoropeptides, may be used in combination with a humoral response-based influenza vaccine, such as Fluzone?, Agrippal?, Begrivac?, Fluvax?, Enzira?, Fluarix?, Flulaval?, FluAd?, Influvac?, Fluvirin?, FluBlok? or any influenza vaccine comprising haemagglutinin as the active component, or a live attenuated influenza virus, including the cold-adapted strains such as Flumist?. Administration may be as a combined mixture or as separate vaccine agents administered contemporaneously or separated by time.

(49) In a further aspect the influenza vaccine formulation may be administered in combination with an anti-viral therapeutic composition, including neuraminidase inhibitor treatments such as amanidine, rimantidine, zanamivir or oseltamivir. Administration may be contemporaneous or separated by time.

(50) In other aspects the invention provides:

(51) i) Use of the immunogenic construct as described herein in the preparation of a medicament for treatment or prevention of a disease or symptoms thereof.

(52) ii) A method of treatment through the induction of an immune response following administration of the formulation described herein.

(53) Role of T Cells in Protection Against Influenza Disease

(54) Whilst conventional influenza vaccine technologies have focused primarily on the antibody responses to the viral surface proteins, these are subject to antigenic shift and drift which undermines efficacy and creates the logistical vulnerabilities described. In contrast, T cells, which mediate cellular immune responses, can target proteins more highly conserved across heterologous viral strains and clades. This property gives vaccines that induce protective cellular immune responses the potential to protect against heterologous viral strains and clades (heterosubtypic immunity). For the influenza virus, conservation of the PB1, PB2, PA, NP, M1, M2, NS1 and NS2 proteins and persistence of the corresponding antigen-specific CD4+ and CD8+ T cells makes these proteins attractive vaccine targets.

(55) Protective antiviral cell-mediated immunity consists of the induction of a Type 1 response supported by Type 1 CD4+ T-helper lymphocytes (Th1) leading to the activation of immune effector mechanisms including the induction and maintenance of cytotoxic T lymphocytes (CTLs) as well as immunostimulatory cytokines such as IFN-? and IL-2. The CD4+ T helper cells are primarily responsible for helping other immune cells through direct cell-cell interactions or by secreting cytokines after recognizing antigenic T cell peptide epitopes bound to major histocompatibility complex (MHC) class II molecules. The cytotoxic T lymphocytes (CTLs) typically express CD8 and induce lysis or apoptosis of cells on which they recognize foreign antigens presented by MHC class I molecules, providing a defense against intracellular pathogens such as viruses. This association of phenotype and function is not absolute, since CD4+ cells may exhibit cytolytic activity, while CD8+ cells secrete antiviral cytokines, notably interferon-? (IFN-?) and tumor necrosis factor. Indeed, CD4.sup.+ CTL activity has been proposed as another immune mechanism to control acute and chronic viral infection in humans. CD4.sup.+ CTL may control viral spread by direct antiviral cytolytic effect and may play a direct antiviral activity by the production of antiviral cytokines such as IFN-?. IFN-? is known to have a direct inhibitory and non-cytolytic effect on virus production. CD4+ T helper cells are also essential in determining B cell antibody response and class switching, and in maximizing bactericidal activity of phagocytes such as macrophages.

(56) Cellular immune responses are believed to play an important role in controlling influenza infection, ameliorating signs of disease and promoting disease recovery. Influenza-specific cellular immunity is elicited following natural infection and several viral proteins have been identified as targets for human memory heterosubtypic T cell responses, including nucleoprotein (NP), polymerase (PB1, PB2, & PA), M1 and M2 proteins, and non-structural protein-1 (NS1). NS2 may also be implicated. These internal proteins contain highly conserved and immunodominant regions making them ideal T cell targets. In particular, experimental studies have shown that influenza-A NP represents an important target antigen for both subtype-specific and cross-reactive CTLs in mice and humans. This contrasts with haemagglutinin (HA) and neuraminidase (NA), which are unsuitable targets due to their high sequence variability within and between influenza subtypes.

(57) More specifically, cell-mediated immunity is strongly implicated in the protection against influenza disease including highly pathogenic strains. Memory CD4+ and CD8+ T cells are present in the lung airways and evidence is mounting that these cells play a role in pulmonary immunity to influenza challenge by mediating engagement of the pathogen at the site of infection when pathogen loads are low. Depletion of CD8+ T cells reduces the capacity of primed mice to respond to influenza infection, which signifies a role for CD8+ T cells in the protective secondary response. Because viral replication is confined to cells in the respiratory epithelium, CD8+ T cells exert their effector functions at this site, producing antiviral cytokines and lysing target cells presenting viral determinants for which they bear a specific T-cell receptor. Lysis of infected epithelial cells is mediated by exocytosis granules containing perforin and granzyme, as well as Fas mechanisms. (Thomas et al. Cell-mediated protection in influenza infection. Emerg Infect Dis. 2006 January; 12(1):48-54).

(58) Vigorous CD4+ T cell responses to influenza are initiated in the draining lymph node followed by the spleen and they peak in the lung and bronchoalveolar secretions at day 6-7 post infection. This primary CD4 T-cell response to influenza infection, albeit smaller in magnitude than the CD8 response, has been shown to involve robust CD4+ expansion, Th-1 differentiation and their migration to the site of infection. CD4+ T-helper cells are also necessary for long lasting and effective CD8 memory to influenza infection. CD4 effector T-cell and memory responses contribute to immunity against influenza via multiple mechanisms including their classic contribution as helpers during the generation of influenza specific CD8+ CTL responses, their ability to drive IgG2a to neutralize infective viral particles, and via their direct antiviral activity through the secretion of IFN-gamma. Both CD4+ and CD8+ T-cell epitopes have been shown to promote viral clearance and confer protection in mice against an influenza challenge.

(59) Mouse models for influenza-A virus provide an experimental system to analyze T-cell mediated immunity. In particular, the T-cell immune response to influenza infection has been well characterized in C57BL/6 (H2.sup.b) and Balb/C (H2.sup.d) mice and their hybrids. Plotnicky et al. The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice. Virology. 2003 May 10; 309(2):320-9.) demonstrated the protective efficacy of the influenza matrix protein (M1) epitope 58-66 to lethal transgenic murine challenge. Protection was mediated by T-cells since protection was abolished following in vivo depletion of CD8+ and/or CD4+ T-cells. Mouse survival correlated with M1-specific T-cells in the lungs, which were directly cytotoxic to influenza-infected cells following influenza challenge. Woodland et al. Identification of protective and non-protective T cell epitopes in influenza. Vaccine. 2006 Jan. 23; 24(4):452-6) also demonstrated that a single CD4+ T cell epitope HA (211-225) could confer partial control of viral infection in vaccinated mice.

(60) Whilst T cell targets tend to be prone to less frequent mutation than the influenza virus surface protein B cell epitopes, CD8+ and CD4+ T cell epitopes will also mutate under protective immune pressure over time (Berkhoff et al. Fitness costs limit escape from cytotoxic T lymphocytes by influenza A viruses. Vaccine. 2006 Nov. 10; 24(44-46):6594-6.). This escape likely results from the confrontation between the virus and the highly polymorphic human leukocyte antigen (HLA) class I and II proteins which determines antigen processing and epitope presentation to host CD8.sup.+ and CD4+ T-cells respectively. This viral escape mechanism has been more clearly established for HIV and HCV and is known to shape the evolution of the virus. Therefore the selection of highly conserved peptide sequences with low inherent variability (entropy) is an important factor to be considered in the design of T-cell vaccines which can specifically counter antigenic shift and drift. Such methods have been described by Berkhoff et al. Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes J Virol. 2005 September; 79(17):11239-46.)

(61) Adults over 65 years of age currently account for approximately 90% of all influenza-related mortality. This is also the target group where current vaccines are least effective. In humans, ageing appears to be associated with a decline in the ability to generate T-cell effectors from memory sub-populations. An increased frequency of central memory CD4+ T-cells and decreased frequency of effector memory CD4+ T cells in the elderly post-vaccination has been observed, which may be related to decreased levels of serum IL-7. Elderly subjects also demonstrate a blunted type-1 T-cell response to influenza vaccination which correlates directly with IgG1 responses. Furthermore, mice also exhibit an age related impairment of epitope-specific CD8+ CTL activity during primary influenza-A infection. This is associated with a defect in expansion of CD8+ CTL rather than effector activity of influenza-specific CD8+ T cells. (Mbawuike et al. Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. Cell Immunol. 1996 Oct. 10; 173(1):64-78.)

(62) As an important element of the T cell response is directed at the clearance of infected cells, a T-cell vaccine may be used in a prophylactic manner to generate memory recall as well as in a therapeutic mode, post-infection, to enhance the host's natural cell-mediated immunity. The T-cell vaccine may also be used in combination with a conventional antibody-generating (humoral response-based) influenza vaccine, either through co-administration or by separate administration.

(63) T-Cell Vaccine Approaches

(64) A review of the T-cell and Influenza vaccine fields highlights a number of critical challenges faced in the design of a broadly cross protective T-cell vaccine. A T-cell vaccine must first be capable of priming and boosting CD4+ HTL and CD8+ CTL T-cell memory and effector functions in a high percentage of vaccine recipients. Such a vaccine must also address viral genetic diversity, and ongoing mutation, as well as human genetic diversity manifest at the level of MHC allele polymorphism. The proposed invention seeks to address these design issues by combining a novel fluoropeptide vaccine delivery system together with highly conserved influenza peptides. The peptides are preferably antigens known to contain one or more epitopes, in particular T-cell epitopes.

(65) Traditional peptide-based T-cell vaccine approaches have been epitope-based and focussed on minimal CTL (8-11aa) or T-helper (13aa) epitopes delivered as single epitopes or reconstituted artificial strings. Non-natural sequences may face inefficient antigen processing constraints as well as giving rise to the potential formation of unrelated neo-epitopes. Long, natural conserved peptide sequences containing overlapping T-cell epitopes, clustered T-cell epitopes or promiscuous T-cell epitopes in a single peptide sequence permit natural antigen processing while achieving broad population coverage. Moreover, the use of multiples of these long natural peptides in the one vaccine formulation is likely to offer even greater population coverage. Precedent shows long peptides (30-35aa) comprising CD4+& CD8+ T-cell epitopes have the ability to induce multi-epitopic responses in animals and humans (Coutsinos et al. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J Virol. 2003 October; 77(20):11220-31.). For an effective anti-viral CTL response (CD8 T cell driven), an appropriate Th-1 cytokine environment is required (ensured by CD4 cells), thus the concomitant delivery of CD4 and CD8 epitopes is predicted to enhance cellular responses (Krowka et al. A requirement for physical linkage between determinants recognized by helper molecules and cytotoxic T cell precursors in the induction of cytotoxic T cell responses J. Immunol 1986, May 15; 136(10):3561-6.).

(66) CD4+ and CD8+ T cells recognize short peptides resulting from the extracellular and intracellular processing of foreign and self proteins, presented bound to specific cell surface molecules encoded by the MHC system. There are two discrete classes of MHC molecules: (i) MHC class I presents endogenous peptides; and (ii) MHC class II presents exogenous peptides. The process of MHC class I antigen presentation involves protein degradation, peptide transport to the endoplasmic reticulum, peptide-MHC binding and export of peptide-MHC complexes to the cell surface for recognition by CD8+ T cells. Peptides are bound within a specific MHC binding groove, the shape and characteristics of which results in the binding of specific subsets of peptides sharing a common binding motif T cells are activated when the T-cell receptor recognizes a specific peptide-MHC complex, and in this way identify cells infected by intracellular parasites or viruses or cells containing abnormal proteins (e.g. tumor cells) and mount appropriate immune responses against them.

(67) The peptides involved in specific peptide-MHC complexes triggering T-cell recognition (T-cell epitopes) are important tools for the diagnosis and treatment of infectious, autoimmune, allergic and neoplastic diseases. Because T-cell epitopes are subsets of MHC-binding peptides, precise identification of portions of proteins that can bind MHC molecules is important for the design of vaccines and immunotherapeutics. The MHC polymorphism is very high in the human population with 580 HLA-A, 921 HLA-B, 312 HLA-C, 527 HLA-DR(beta), 127 HLA-DRQ(beta) and 86 HLA-DQ(beta) alleles known to date. This situation is challenging when having to design a T-cell based vaccine with broad population coverage. MHC-binding peptides contain position-specific amino acids that interact with the groove of the MHC molecule(s), contributing to peptide binding. The preferred amino acids at each position of the binding motif may vary between allelic variants of MHC molecules. Computational models facilitate identification of peptides that bind various MHC molecules. A variety of computational methods, MHC binding assays, X-ray crystallography study and numerous other methods known in the art permit the identification of peptides that bind to MHC molecules. Novel in silico antigen identification methodologies offer the ability to rapidly process the large amounts of data involved in screening peptide sequences for HLA binding motifs necessary to delineate viral sequences useful for a T cell vaccine. HLA based bioinformatics approaches have been successfully applied in many fields of immunology and make it possible to address human genetic diversity concerns, for example: Depil et al. Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies., J Immunother (1997). 2007 February-March; 30(2):215-26; Frahm et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol. 2007 Aug. 17; 37(9):2419-2433; Schulze zur Wiesch et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled Hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol. 2005 Sep. 15; 175(6):3603-13; Doolan et al. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol. 2000 Jul. 15; 165(2):1123-37.).

(68) Peptides that bind more than one MHC allelic variant (promiscuous peptides) are prime targets for vaccine and immunotherapy development because they are relevant to a greater proportion of the human population. Promiscuous CD4+ T cell epitopes were also reported to bind multiple MHC class II molecules. (Panina-Bordignon et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol. 1989 December; 19(12):2237-42.) On the other hand, some promiscuous CD8+ T cell epitopes were previously described having the ability to bind multiples MHC class I molecules sharing binding characteristics and forming a so-called supertype (Frahm et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol. 2007 Aug. 17; 37(9):2419-2433; Sette et al. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol. 1998 August; 10(4):478-82). The identification of promiscuous CD4+ and CD8+ T cell epitopes represent an important strategy in vaccine design in order to achieve broad population coverage. MHC polymorphism is also addressed by selecting peptides known or predicted to contain an MHC binding motif related to highly frequent MHC alleles in a specific ethnic group or across multiple ethnic groups.

(69) By selecting a combination of sequences that provide broad population coverage and are conserved across a range of influenza strains (identified by using, for example, the National Center for Biotechnology Information (NCBI) or Los Alamos National Laboratory (LANL) influenza sequence databases) one is able to address viral genetic diversity and achieve protection against the majority, if not all, relevant influenza strains.

(70) Historically, the key failings of T-cell vaccine technologies (DNA and viral vector vaccines) have been the low percentage of vaccine subjects responding to the vaccines, often low levels of immunogenicity and their ability to achieve a booster amplification of memory and effector T-cell responses. The principal goal for an effective influenza T-cell vaccine is to promote robust T-cell memory responses such that on re-exposure to antigen there is rapid expansion of effector functions which control viral load and promote viral clearance from the lungs. To achieve this, robust virus specific Th-1 directed CD4+& CD8+ T-cell central and effector memory responses are required. For a viable, commercial product this response must be elicited in a high percentage of vaccine recipients (>90%) and be capable of generating long term memory responses which will be required for memory recall and subsequent disease protection post-infection. However, to generate this type of durable immunity a vaccine must also achieve a robust booster amplifying effect with repeat vaccine exposure.

(71) Current immunological strategies to improve the cellular immunity induced by vaccines and immunotherapeutics include the development of live attenuated versions of the pathogen and the use of live vectors to deliver appropriate antigens or DNA coding for such antigens. Such approaches, which invariably fail to generate a meaningful booster response in unselected populations, have led to convoluted prime-boost combinations and are also limited by safety considerations within an increasingly stringent regulatory environment. In addition, issues arising from the scalability of manufacturing processes and prohibitive costs often limit the commercial viability of products of biological origin. In this context, synthetic peptides are very attractive antigens as they are chemically well-defined, highly stable and can be designed to contain T and/or B cell epitopes.

(72) In order to stimulate T lymphocyte responses in vivo, synthetic peptides contained in a vaccine or an immunotherapeutic product should preferably be internalized by antigen presenting cells and especially dendritic cells. Dendritic cells (DCs) play a crucial role in the initiation of primary T-cell mediated immune responses. These cells exist in two major stages of maturation associated with different functions. Immature dendritic cells (iDCs) are located in most tissues or in the circulation and are recruited into inflamed sites in the body. They are highly specialised antigen-capturing cells, expressing large amounts of receptors involved in antigen uptake and phagocytosis. Following antigen capture and processing, iDCs move to local T-cell locations in the lymph nodes or spleen. During this process, DCs lose their antigen-capturing capacity turning into immunostimulatory mature DCs (mDCs).

(73) Dendritic cells are efficient presenting cells that initiate the host's immune response to peptide antigen associated with class I and class II MHC molecules. They are able to prime na?ve CD4 and CD8 T-cells. According to current models of antigen processing and presentation pathways, exogeneous antigens are internalised into the endocytic compartments of antigen presenting cells where they are degraded into peptides, some of which bind to MHC class II molecules. The mature MHC class II/peptide complexes are then transported to the cell surface for presentation to CD4 T-lymphocytes. In contrast, endogenous antigen is degraded in the cytoplasm by the action of the proteosome before being transported into the cytoplasm where they bind to nascent MHC class I molecules. Stable MHC class I molecules complexed to peptides are then transported to the cell surface to stimulate CD8 CTL. Exogenous antigen may also be presented on MHC class I molecules by professional APCs in a process called cross-presentation. Phagosomes containing extracellular antigen may fuse with reticulum endoplasmic and antigen may gain the machinery necessary to load peptide onto MHC class I molecules

(74) The Examples herein highlight the differential T-cell immune response obtained by the attachment of a fluorocarbon vector to antigens compared to the corresponding non-fluorinated antigens. The eight (8) antigens exemplified were selected from the list of Influenza sequences herein defined. This provisional selection utilized a proprietary selection algorithm encompassing a combination of parameters including; immunoinformatics selection, in-vitro binding assays, ex-vivo restimulation assays using human PBMC previously infected with influenza, manufacturing and formulation parameters. Finally the assessment in mice confirmed that fluoropeptides thus selected either individually or in combination were immunogenic and the responses obtained were superior to the native peptide antigens. The antigen selection focus and desire to utilize a combination of antigens for this vaccine prototype is such that both viral genetic and human HLA diversity are addressed in this rational vaccine design. This has been one of the key failings in the peptide vaccine field. Whilst it is possible to utilize a single antigen in the fluoropeptide vaccine it would limit the vaccine's immunogenicity potential in an outbred human (or other) population and therefore the selection of multiple peptides is essential for a broadly effective vaccine.

(75) As used herein (e.g., in the figures) the term fluoropepetides refers to fluorocarbon vectors (chains) conjugated to peptide based antigens. The Examples refer to the figures in which:

(76) FIG. 1 shows a comparison of the immunogenicity of a multivalent fluoropeptide vaccine versus its native peptide equivalent in BALB/c and CBF6 mice, after prime or prime-boost, assessed by ex vivo IFN-? ELIspot assay. Seven or eight mice per group were immunized subcutaneously with the fluoropeptide vaccine (composed of 8 formulated fluoropeptides at a dose of 1 nmol per fluoropeptide in 100 ?l) or the equivalent native peptides (composed of 8 formulated native peptides at a dose of 1 nmol per peptide in 100 ?l). The control group received a formulation containing excipient only. Ten days after the final injection mice were sacrificed by cervical dislocation. Spleens were removed and single spleen cell suspensions were prepared from individual mice. Murine IFN-? ELISpot assays (Mabtech, Sweden) were performed according to manufacturer's instructions. Spleen cells (5?10.sup.5) were stimulated, in duplicate, with 8 individual native peptides at a concentration of 10 ?g/ml per peptide in complete culture medium (RPMI supplemented with 10% Foetal Calf Serum) in a total volume of 200 ?l for 18 hours at 37? C. and 5% CO.sub.2. The spots were counted using a CTL-immunospot reader unit. For each mouse, the ft) total number of spots was cumulated for all 8 peptides and the value of the control wells (media only) was subtracted 8 times. The results correspond to mean?standard deviation of spot forming cells (SFC) per million input spleen cells.

(77) FIG. 2 shows a comparison of the immunogenicity of a multivalent fluoropeptide vaccine versus its native peptide equivalent in BALB/c and CBF6 mice, after prime or prime-boost, assessed by ex vivo IFN-? ELIspot assay. Seven or eight mice per group were immunized subcutaneously with the fluoropeptide vaccine (composed of 8 formulated fluoropeptides at a dose of 1 nmol per fluoropeptide in 100 ?l) or the equivalent native peptides (composed of 8 formulated native peptides at a dose of 1 nmol per peptide in 100 ?l). The control group received a formulation containing excipient only. Ten days after the final injection mice were sacrificed by cervical dislocation. Spleens were removed and single spleen cell suspensions were prepared from individual mice. Murine IFN-? ELISpot assays (Mabtech, Sweden) were performed according to manufacturer's instructions. Spleen cells (5?10.sup.5) were stimulated, in duplicate, with a mixture of 8 peptides at a concentration of 1 ?g/ml per peptide in complete culture medium (RPMI supplemented with 10% Foetal Calf Serum) in a total volume of 200 ?l for 18 hours at 37? C. and 5% CO.sub.2. The spots were counted using a CTL-immunospot reader unit. For each mouse, the total number of spots was cumulated for all 8 peptides and the value of the control wells (media only) was subtracted 8 times. The results correspond to mean?standard deviation of spot forming cells (SFC) per million input spleen cells.

(78) FIG. 3 shows a comparison of individual peptide immunogenicity of fluoropeptides verses native peptides in BALB/c and CBF6 mice after prime or prime-boost assessed by ex vivo IFN-? ELISpot. Seven or eight mice per group were immunized subcutaneously with the fluoropeptide vaccine (composed of 8 formulated fluoropeptides at a dose of 1 nmol per fluoropeptide in 100 ?l) or the equivalent native peptides (composed of 8 formulated native peptides at a dose of 1 nmol per peptide in 100 ?l). The control group received a formulation containing excipient only. Ten days after the last injection mice were sacrificed by cervical dislocation. Spleens were removed and single spleen cell suspensions were prepared from individual mice. Murine IFN-? ELISpot assays (Mabtech, Sweden) were performed according to manufacturer's instructions. Spleen cells (5?10.sup.5) were stimulated, in duplicate, with 8 individual native peptides at a concentration of 10 ?g/ml per peptide in complete culture medium (RPMI supplemented with 10% Foetal Calf Serum) in a total volume of 200 ?l for 18 hours at 37? C. under 5% CO.sub.2 atmosphere. The spots were counted using a CTL-immunospot reader unit. The results correspond to mean?standard deviation of spot forming cells (SFC) per million input spleen cells.

(79) FIG. 4 shows a comparison of the immunogenicity of a multivalent fluoropeptide vaccine versus its native peptide equivalent in BALB/c and CBF6 mice after prime-boost immunization; assessment of cytokine profiles. Eight mice per group were immunized subcutaneously with the fluoropeptide vaccine (composed of 8 formulated fluoropeptides at a dose of 1 nmol per fluoropeptide in 100 ?l) or the equivalent native peptides (composed of 8 formulated native peptides at a dose of 1 nmol per peptide in 100 ?l). The control groups of mice were injected with a formulation containing excipient only. Mice were immunized at a 15 day interval. Ten days after the last injection mice were sacrificed by cervical dislocation. Spleens were removed and single spleen cell suspensions were prepared from individual mice. Splenocytes were stimulated with a mixture of 8 native peptides at a concentration of 1 ?g/ml per peptide in complete culture medium (RPMI supplemented with 10% Foetal Calf Serum) in a total volume of 200 ?l for 48 hours at 37? C. under 5% CO.sub.2 atmosphere. Analysis of cytokine concentrations (interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interferon-? (IFN-?), and Tumor Necrosis Factor (TNF)) from the culture supernatants of stimulated cells was conducted using a murine cytometric bead array kit (CBA; BD Biosciences, UK) according to manufacturer's instructions and was analyzed using a FacsCanto II flow cytometer. Standard curves were determined for each cytokine from a range of 210-2500 pg/ml. The lower limit of detection for the CBA, according to the manufacturer, is 2.5-3.2 pg/ml, depending on the analyte. The results correspond to mean values and standard deviation calculated for each group of mice for each cytokine. Results are expressed as cytokine concentration in pg/ml.

(80) FIG. 5 is a graph showing that both CD4+ T cells and CD8+ T cells are stimulated by the fluoropeptide vaccine in BALB/c mice. Four mice per group were immunized subcutaneously with the fluoropeptide vaccine (composed of 8 formulated fluoropeptides at a dose of 1 nmol per fluoropeptide in 100 ?l). Mice received 2 injections (prime-boost) at a 15 day interval. Ten days after the last injection, mice were sacrificed by cervical dislocation. Spleens were removed and single spleen cell suspensions were prepared from individual mice. Cells were resuspended at 0.5?10.sup.6/well and stimulated with media only or a mixture of 8 native peptides (vaccine) for 72 hours at 37? C. and 5% CO.sub.2. Positive control cultures (PMA/I) received 50 ng/ml PMA and 0.5 ?g/ml ionomycin for the final 5 hours of culture. All cultures received 10 ?l/ml Brefeldin A for the final 5 hours of culture. Cells were stained extracellularly for CD4 and CD8, and intracellularly for IFN-?, and analyzed by flow cytometry using a BD FACSCanto II cytometer. Results for individual mice are shown as percentage of CD4+ or CD8+ T cells expressing intracellular IFN-?.

(81) FIG. 6 shows a comparison of the immunogenicity of a multivalent fluoropeptide vaccine versus vaccine emulsified in CFA in BALB/c mice after a single immunization; assessment of cytokine profiles. Ten mice per group were immunized subcutaneously with the fluoropeptide vaccine (composed of 8 formulated fluoropeptides at a dose of 1 nmol per fluoropeptide in 100 ?l) or fluoropeptide vaccine emulsified in complete Freund's adjuvant (CFA). The control group of mice was injected with a formulation containing excipient only. Ten days later mice were sacrificed by cervical dislocation. Spleens were removed and single spleen cell suspensions were prepared from individual mice. Splenocytes were stimulated with a mixture of 8 native peptides at a concentration of 1 ?g/ml per peptide in complete culture medium (RPMI supplemented with 10% Foetal Calf Serum) in a total volume of 200 ?l for 48 hours at 37? C. under 5% CO.sub.2 atmosphere. Analysis of cytokine concentrations (interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interferon-? (IFN-?), and Tumor Necrosis Factor (TNF)) from the culture supernatants of stimulated cells was conducted using a murine cytometric bead array kit (CBA; BD Biosciences, UK) according to manufacturer's instructions and was analyzed using a FacsCanto II flow cytometer. Standard curves were determined for each cytokine from a range of 2.5-2500 pg/ml. The lower limit of detection for the CBA, according to the manufacturer, is 2.5-3.2 pg/ml, depending on the analyte. The results correspond to mean values?standard error calculated for each group of mice for each cytokine. Results are expressed as mean cytokine concentration in pg/ml.

(82) FIG. 7 shows a comparison of subcutaneous versus intradermal routes of fluoropeptide vaccine administration in BALB/c mice after a single immunization: ex vivo IFN-? ELISpot assay. Ten mice per group were immunized subcutaneously (s.c.) or intradermally (i.d.) with the fluoropeptide vaccine (composed of 8 formulated fluoropeptides at a dose of 1 nmol per fluoropeptide in 100 ?l). The control group received a formulation containing excipient only administered subcutaneously. Ten days later mice were sacrificed by cervical dislocation. Spleens were removed and single spleen cell suspensions were prepared from individual mice. Murine IFN-? ELISpot assays (Mabtech, Sweden) were performed according to manufacturer's instructions. Spleen cells (5?10.sup.5) were stimulated, in duplicate, with 8 individual native peptides at a concentration of 10 ?g/ml per peptide in complete culture medium (RPMI supplemented with 10% Foetal Calf Serum) in a total volume of 200 ?l for 18 hours at 37? C. under 5% CO.sub.2 atmosphere. The spots were counted using a CTL-immunospot reader unit. For each mouse, the total number of spots was cumulated for all 8 peptides and the value of the control wells (media only) was subtracted 8 times. The results correspond to mean?standard error of spot forming cells (SFC) per million input spleen cells.

(83) In light of the foregoing description, the specific non-limiting examples presented below are for illustrative purposes and not intended to limit the scope of the invention in any way.

EXAMPLES

Example 1

(84) Example Peptides

(85) Candidates for conjugating to a fluorocarbon vector for inclusion into a prophylactic or therapeutic vaccine for influenza may include the following one or more peptides or fragments thereof, or homologues (including the corresponding consensus, ancestral or central tree sequences as referred to in the Los Alamos National Laboratory influenza sequence database (Macken, C., Lu, H., Goodman, J., & Boykin, L., The value of a database in surveillance and vaccine selection. in Options for the Control of Influenza IV. A. D. M. E. Osterhaus, N. Cox & A. W. Hampson (Eds.) 2001, 103-106.) or Influenza virus resources at NCBI) or natural and non-natural variants thereof, but not necessarily exclusively. Specific examples of appropriate peptides are given below where the standard one letter code has been utilized. Homologues have at least a 50% identity compared to a reference sequence. Preferably a homologue has 80, 85, 90, 95, 98 or 99% identity to a naturally occurring sequence. The use of non-natural amino acids must not interfere with the ability of the peptide to bind to MHC class I or II receptors. Fragments of these sequences that contain one or more epitopes are also candidate peptides for attachment to the fluorocarbon vector.

(86) These sequences were selected from Influenza A consensus sequences. The influenza virus protein and the position of the peptide within that protein are specified. Protein sequences were collected from the Influenza virus resource web site, at ncbi.nlm.nih.gov/genomes/FLU/.

(87) TABLE-US-00007 SEQIDNo1 PB2Position027to061 HMAIIKKYTSGRQEKNPSLRMKWMMAMKYPITADK(SEQIDNO:1) SEQIDNo2 PB2Position123to157 ERLKHGTFGPVHFRNQVKIRRRVDINPGHADLSAK(SEQIDNO:2) SEQIDNo3 PB2Position155to189 SAKEAQDVIMEVVFPNEVGARILTSESQLTITKEK(SEQIDNO:3) SEQIDNo4 PB2Position203to237 VAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQG(SEQIDNO:4) SEQIDNo5 PB2Position249to283 EVRNDDVDQSLIIAARNIVRRAAVSADPLASLLEM(SEQIDNO:5) SEQIDNo6 PB2Position358to392 EGYEEFTMVGRRATAILRKATRRLIQLIVSGRDEQ(SEQIDNO:6) SEQIDNo7 PB2Position370to404 ATAILRKATRRLIQLIVSGRDEQSIAEAIIVAMVF(SEQIDNO:7) SEQIDNo8 PB2Position415to449 RGDLNFVNRANQRLNPMHQLLRHFQKDAKVLFQNW(SEQIDNO:8) SEQIDNo9 PB2Position532to566 SSSMMWEINGPESVLVNTYQWIIRNWETVKIQWSQ(SEQIDNO:9) SEQIDNo10 PB2Position592to626 YSGFVRTLFQQMRDVLGTFDTVQIIKLLPFAAAPP(SEQIDNO: 10) SEQIDNo11 PB2Position607to641 LGTFDTVQIIKLLPFAAAPPEQSRMQFSSLTVNVR(SEQIDNO: 11) SEQIDNo12 PB2Position627to659 QSRMQFSSLTVNVRGSGMRILVRGNSPVFNYNK(SEQIDNO:12) SEQIDNo13 PB1Position012to046 VPAQNAISTTFPYTGDPPYSHGTGTGYTMDTVNRT(SEQIDNO: 13) SEQIDNo14 PB1Position114to148 VQQTRVDKLTQGRQTYDWTLNRNQPAATALANTIE(SEQIDNO: 14) SEQIDNo15 PB1Position216to250 SYLIRALTLNTMTKDAERGKLKRRAIATPGMQIRG(SEQIDNO: 15) SEQIDNo16 PB1Position267to301 EQSGLPVGGNEKKAKLANVVRKMMTNSQDTELSFT(SEQIDNO: 16) SEQIDNo17 PB1Position324to358 YITRNQPEWFRNVLSIAPIMFSNKMARLGKGYMFE(SEQIDNO: 17) SEQIDNo18 PB1Position340to374 APIMFSNKMARLGKGYMFESKXMKLRTQIPAEMLA(SEQIDNO: 18) SEQIDNo19 PB1Position404to436 SPGMMMGMFNMLSTVLGVSILNLGQKKYTKTTY(SEQIDNO:19) SEQIDNo20 PB1Position479to513 KKKSYINKTGTFEFTSFFYRYGFVANFSMELPSFG(SEQIDNO: 20) SEQIDNo21 PB1Position486to520 KTGTFEFTSFFYRYGFVANFSMELPSFGVSGINES(SEQIDNO: 21) SEQIDNo22 PB1Position526to560 GVTVIKNNMINNDLGPATAQMALQLFIKDYRYTYR(SEQIDNO: 22) SEQIDNo23 PB1Position656to690 EYDAVATTHSWIPKRNRSILNTSQRGILEDEQMYQ(SEQIDNO: 23) SEQIDNo24 PB1Position700to734 FPSSSYRRPVGISSMVEAMVSRARIDARIDFESGR(SEQIDNO: 24) SEQIDNo25 PAPosition107to141 PDLYDYKENRFIEIGVTRREVHIYYLEKANKIKSE(SEQIDNO: 25) SEQIDNo26 PAPosition122to156 VTRREVHIYYLEKANKIKSEKTHIHIFSFTGEEMA(SEQIDNO: 26) SEQIDNo27 PAPosition145to179 IHIFSFTGEEMATKADYTLDEESRARIKTRLFTIR(SEQIDNO: 27) SEQIDNo28 PAPosition166to200 ESRARIKTRLFTIRQEMASRGLWDSFRQSERGEET(SEQIDNO: 28) SEQIDNo29 PAPosition495to529 RRKTNLYGFIIKGRSHLRNDTDVVNFVSMEFSLTD(SEQIDNO: 29) SEQIDNo30 PAPosition642to676 AKSVFNSLYASPQLEGFSAESRKLLLIVQALRDNL(SEQIDNO: 30) SEQIDNo31 PAPosition173to207 PRRSGAAGAAVKGVGTMVMELIRMIKRGINDRNFW(SEQIDNO: 31) SEQIDNo32 NPPosition240to274 DQVRESRNPGNAEIEDLIFLARSALILRGSVAHKS(SEQIDNO: 32) SEQIDNo33 M1Position002to026 SLLTEVETYVLSIIPSGPLKAEIAQRLEDVFAGKN(SEQIDNO: 33) SEQIDNo34 M1Position023to057 EIAQRLEDVFAGKNTDLEALMEWLKTRPILSPLTK(SEQIDNO: 34) SEQIDNo35 M1Position038to072 DLEALMEWLKTRPILSPLTKGILGFVFTLTVPSER(SEQIDNO: 35) SEQIDNo36 M1Position055to089 LTKGILGFVFTLTVPSERGLQRRRFVQNALNGNGD(SEQIDNO: 36) SEQIDNo37 M1Position166to200 ATTTNPLIRHENRMVLASTTAKAMEQMAGSSEQAA(SEQIDNO: 37) SEQIDNo38 NS1Position128to162 IILKANFSVIFDRLETLILLRAFTEEGAIVGEISP(SEQIDNO: 38) SEQIDNo39 NS2Position026to060 EDLNGMITQFESLKLYRDSLGEAVMRMGDLHSLQN(SEQIDNO: 39)

(88) The following sequences were selected from Influenza B consensus sequences. The influenza virus protein and the position of the peptide within that protein are specified. Protein sequences were collected from the Influenza virus resource web site, at ncbi.nlm.nih.gov/genomes/FLU/:

(89) TABLE-US-00008 SEQIDNo40 PB2Position016to050 NEAKTVLKQTTVDQYNIIRKFNTSRIEKNPSLRMK(SEQIDNO: 40) SEQIDNo41 PB2Position117to151 YESFFLRKMRLDNATWGRITFGPVERVRKRVLLNP(SEQIDNO: 41) SEQIDNo42 PB2Position141to175 ERVRKRVLLNPLTKEMPPDEASNVIMEILFPKEAG(SEQIDNO: 42) SEQIDNo43 PB2Position197to231 GTMITPIVLAYMLERELVARRRFLPVAGATSAEFI(SEQIDNO: 43) SEQIDNo44 PB2Position311to345 DIIRAALGLKIRQRQRFGRLELKRISGRGFKNDEE(SEQIDNO: 44) SEQIDNo45 PB2Position404to438 MVFSQDTRMFQGVRGEINFLNRAGQLLSPMYQLQR(SEQIDNO: 45) SEQIDNo46 PB2Position519to553 VSELESQAQLMITYDTPKMWEMGTTKELVQNTYQW(SEQIDNO: 46) SEQIDNo47 PB2Position537to571 MWEMGTTKELVQNTYQWVLKNLVTLKAQFLLGKED(SEQIDNO: 47) SEQIDNo48 PB2Position572to606 MFQWDAFEAFESIIPQKMAGQYSGFARAVLKQMRD(SEQIDNO: 48) SEQIDNo49 PB2Position717to751 LEKLKPGEKANILLYQGKPVKVVKRKRYSALSNDI(SEQIDNO: 49) SEQIDNo50 PB1Position001to035 MNINPYFLFIDVPIQAAISTTFPYTGVPPYSHGTG(SEQIDNO: 50) SEQIDNo51 PB1Position097to131 EEHPGLFQAASQNAMEALMVTTVDKLTQGRQTFDW(SEQIDNO: 51) SEQIDNo52 PB1Position227to261 MTKDAERGKLKRRAIATAGIQIRGFVLVVENLAKN(SEQIDNO: 52) SEQIDNo53 PB1Position393to427 KPFFNEEGTASLSPGMMMGMFNMLSTVLGVAALGI(SEQIDNO: 53) SEQIDNo54 PB1Position616to650 DPEYKGRLLHPQNPFVGHLSIEGIKEADITPAHGP(SEQIDNO: 54) SEQIDNo55 PB1Position701to735 SASYRKPVGQHSMLEAMAHRLRMDARLDYESGRMS(SEQIDNO: 55) SEQIDNo56 PAPosition160to194 SSLDEEGKGRVLSRLTELQAELSLKNLWQVLIGEE(SEQIDNO: 56) SEQIDNo57 PAPosition491to525 ESFDMLYGLAVKGQSHLRGDTDVVTVVTFEFSSTD(SEQIDNO: 57) SEQIDNo58 PAPosition696to723 VIQSAYWFNEWLGFEKEGSKVLESVDEIMDE(SEQIDNO:58) SEQIDNo59 NPPosition173to207 FLKEEVKTMYKTTMGSDGFSGLNHIMIGHSQMNDV(SEQIDNO: 59) SEQIDNo60 NPPosition253to287 EAIRFIGRAMADRGLLRDIKAKTAYEKILLNLKNK(SEQIDNO: 60) SEQIDNo61 NPPosition308to342 IADIEDLTLLARSMVVVRPSVASKVVLPISIYAKI(SEQIDNO: 61) SEQIDNo62 NPPosition338to372 IYAKIPQLGFNVEEYSMVGYEAMALYNMATPVSIL(SEQIDNO: 62) SEQIDNo63 NPPosition418to452 GFHVPAKEQVEGMGAALMSIKLQFWAPMTRSGGNE(SEQIDNO: 63) SEQIDNo64 M1Position166to300 ARSSVPGVRREMQMVSAMNTAKTMNGMGKGEDVQK(SEQIDNO: 64) SEQIDNo65 M1Position209to237 IGVLRSLGASQKNGEGIAKDVMEVLKQSS(SEQIDNO:65)

(90) Candidate peptides for inclusion into a prophylactic or therapeutic vaccine for influenza may be peptides from any of the viral proteins haemagglutinin, neuraminidase, matrix (M1) protein, M2, nucleoprotein (NP), PA, PB1, PB2, NS1 or NS2 in any such combination.

(91) Synthesis of Fluoropeptides and Native Peptides (Unmodified Peptides)

(92) Eight native peptides and 8 fluoropeptides (selected from the peptide list contained herein; SEQ ID No 1 through 65) were obtained by solid phase peptide synthesis (SPPS). All peptides were synthesized on Rink amide PEG resin by using standard 9-fluorenyhnethoxycarbonyl (Fmoc) chemistry. The peptide chain was assembled on resin by repetitive removal of the Fmoc protecting group by treating with 20% piperidine/N,N-Dimethylformamide for 30 minutes and coupling of protected amino acid by using 1,3-diisopropylcarbodiimide/1-hydroxy-benzotriazole/N-methylmorpholine for 120 minutes. Ninhydrin test was performed after each coupling to check the coupling efficiency. After the addition of the N-terminal Lysinyl residue, the resin blocks were split to allow (1) on the first half of the resin, the incorporation of the 2H,2H,3H,3H-Perfluoroundecanoic acid fluorocarbon chain (C.sub.8F.sub.17(CH.sub.2).sub.2COOH) on the Epsilon-chain of the N-terminal lysine to derive the fluoropeptide and (2) on the second half of the resin, the acetylation of the Epsilon-chain of the N-terminal lysine to derive the native peptide. Resins were washed and dried, then treated with reagent K for cleavage and removal of the side chain protecting groups. Crude peptides were precipitated from cold ether and collected by filtration. Purity was assessed by RP-HPLC and was superior to 92% for all peptides. Freeze-dried fluoropeptides were prepared under nitrogen and stored at ?20? C. Stability of the fluoropeptides under storage conditions have been confirmed by RP-HPLC and LC-MS over 6 months.

(93) Vaccine Dose Preparation

(94) Eight freeze-dried fluoropeptides (fluoropeptide 1, fluoropeptide 2, fluoropeptide 3, fluoropeptide 4, fluoropeptide 5, fluoropeptide 6, fluoropeptide 7 & fluoropeptide 8) or eight freeze-dried equivalent native peptides (peptide 1, peptide 2, peptide 3, peptide 4, peptide 5, peptide 6, peptide 7 & peptide 8) were formulated to create an isomolar formulation yielding a broadly neutral pH for parenteral delivery.

(95) The sequences of the influenza peptide portions of the constructs were as follows (shown with an NH.sub.2 cap on the carboxy terminus):

(96) TABLE-US-00009 Fluoropeptide1 (SEQIDNO:1) HMAIIKKYTSGRQEKNPSLRMKWMMAMKYPITADK-NH.sub.2 Fluoropeptide2 (SEQIDNO:4) VAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQG-NH2 Fluoropeptide3 (SEQIDNO:17) YITRNQPEWFRNVLSIAPIMFSNKMARLGKGYMFE-NH2 Fluoropeptide4 (SEQIDNO:18) APIMFSNKMARLGKGYMFESKXMKLRTQIPAEMLA-NH2 Fluoropeptide5 (SEQIDNO:19) SPGMMMGMFNMLSTVLGVSILNLGQKKYTKTTY-NH2 Fluoropeptide6 (SEQIDNO:20) KKKSYINKTGTFEFTSFFYRYGFVANFSMELPSFG-NH2 Fluoropeptide7 (SEQIDNO:32) DQVRESRNPGNAEIEDLIFLARSALILRGSVAHKS-NH2 Fluoropeptide8 (SEQIDNO:35) DLEALMEWLKTRPILSPLTKGILGFVFTLTVPSER-NH2
Animals and Immunization

(97) Female, 6-8 weeks of age, BALB/c or CB6F1 (BALB/c?C57BL/6J) mice were purchased from Charles River (UK) &/or Harlan (UK). Injections were performed subcutaneously using 1 ml syringe and 22-G needle. Immunizations were performed so that mice received either a single immunization (prime) or two immunizations (prime/boost). Immunizations were performed with a 14 day interval between each injection.

(98) Fluoropeptide Vaccine is Strongly Immunogenic and is Superior to Native Peptides in Both BALB/c and CB6F1 Mice

(99) The immunogenicity of the fluoropeptide vaccine (mixture of 8 fluoropeptides as above) was compared to the native peptide equivalent (mixture of 8 unmodified peptidescalled native peptides as above) in BALB/c and CB6F1 mice. The study also compared the immunogenicity of both formulations using a prime or prime-boost regimen. Both formulations were injected subcutaneously without adjuvant in BALB/c and CBF6 mice. Mice were immunized with a fluoropeptide vaccine dose containing 1 nmol/fluoropeptide (8 nmol total for eight fluoropeptides) or the native peptide vaccine equivalent at 1 nmol/peptide (8 nmol total for eight native peptides). Neither vaccine preparation contained any adjuvant. 10 days after the final immunization, spleen cells were restimulated with each individual native peptide at 10 ?g/ml and assessed using an IFN-? ELISpot assay. According to ex vivo IFN-? ELISpot assays (FIGS. 1 & 2), the immunogenicity of the fluoropeptide vaccine was superior to both the excipient alone and the native peptide vaccine equivalent after a prime-boost immunization regimen (P<0.001). The results also demonstrated a strong increase in the number of spot forming cells using a prime-boost regimen compared to a single immunization for the fluoropeptide vaccine group only (FIGS. 1 & 2). These results demonstrate the self-adjuvanticity property of the fluorocarbon chain linked to a peptide sequences.

(100) Fluoropeptide Vaccine Induces a Robust Multiepitopic T Cell Response in Both BALB/c and CB6F1 Mice

(101) The immunogenicity of the fluoropeptide vaccine (mixture of 8 fluoropeptides as above) was compared to its native peptide equivalent (mixture of 8 unmodified peptidesreferred to as native peptides as above) in BALB/c and CB6F1 mice. The study also compared the immunogenicity of both formulations on a prime and prime-boost regimen. Both formulations were injected subcutaneously without adjuvant in BALB/c and CB6F1 mice. Mice were immunized with a fluoropeptide vaccine dose containing 1 nmol/fluoropeptide (8 nmol total for eight fluoropeptides), the native peptide vaccine equivalent at 1 nmol/peptide (8 nmol total for eight native peptides). Neither vaccine preparation contained any adjuvant. The control group consisted of mice immunized with excipient alone. 10 days after immunization, spleen cells were restimulated by each individual native peptide at 10 ?g/ml and assessed using IFN-? ELISpot assay. The fluoropeptide vaccine induce peptide-specific responses directed against 5 out of 8 peptides in BALB/c mice and 7 out of 8 peptides in CB6F1 mice which is superior to the response induced by the vaccine equivalent (unmodified peptides). This demonstrates that vaccination with fluoropeptides can induce an immunological response that is both qualitatively and quantitatively superior to that of its native peptide equivalent.

(102) The Fluoropeptide Vaccine Induces a Th1 Cytokine Profile Depending Upon the Murine Strain Tested

(103) The immunogenicity of the fluoropeptide vaccine (mixture of 8 fluoropeptides as above) was compared to the native peptide equivalent (mixture of 8 unmodified peptides as above) in BALB/c and CB6F1 mice. Formulations were injected subcutaneously without adjuvant in BALB/c and CB6F1 mice. Mice were immunized with a fluoropeptide vaccine dose containing 1 nmol/fluoropeptide (8 nmol total for eight fluoropeptides), the native peptide vaccine equivalent at 1 nmol/peptide (8 nmol total for eight native peptides). Neither vaccine preparation contained any adjuvant. 10 days after the last immunization, spleen cells were restimulated with a mixture of 8 native peptides at 1 ?g/ml per peptide. After 48 hours stimulation culture supernatants were assessed for cytokines by means of a multiplexed bead assay (CBA). Results demonstrate the cytokine profile in CBF6 mice is dominated by the production of IFN-? and significant production of TNF-? highlighting a Th1 profile (FIG. 4). This Th1-dominated cytokine profile was more pronounced compared to BALB/c mice due to a lower intensity of these Th1 responses compared to CB6F1 mice (as also observed by IFN-? ELISpotrefer to FIGS. 1 & 2) and increases in Th2 cytokines. Nevertheless, an enhanced Th1 response was observed in BALB/c mice immunized with fluoropeptides compared to its native peptide equivalent.

(104) The Fluoropeptide Vaccine Stimulates Both Peptide-Specific CD4+ and CD8+ T Cells Producing IFN-?

(105) Intracellular cytokine staining for IFN-? was used to provide information about the frequency of peptide-specific CD4+ and CD8+ T cells producing IFN-?. Mice were immunized with the fluoropeptide vaccine (mixture of 8 fluoropeptides as above) and CD4+ or CD8+ splenocytes were assessed for intracellular cytokine staining by flow cytometry after a short stimulation period with a mixture of 8 native peptides (vaccine). The results demonstrate that immunization of mice with the fluoropeptide vaccine was able to elicit both peptide-specific CD4+ and CD8+ T cells producing IFN-? at a frequency of 0.5-2.6% (FIG. 5). This validates that fluoropeptides engage both MHC class I & II antigen processing peptides if the peptides contain relevant MHC class I & II epitopes.

Example 2. Immune Responses Elicited by Fluoropeptide Vaccination are Boosted by Combination with Adjuvant

(106) Immunogenicity of the fluoropeptide vaccine (mixture of 8 fluoropeptides as above) was compared with immunogenicity of the fluoropeptide vaccine in the presence of an adjuvant, Freund's complete adjuvant (FCA). Fluoropeptide vaccine (1 nmol/peptide) or fluoropeptide vaccine (1 nmol/peptide) emulsified in CFA was used to immunize BALB/c mice. 10 days after the immunization, splenocytes were stimulated with individual peptides at 10 ?g/ml. 48 hours later culture supernatants were collected and tested for cytokines using a multiplex cytokine assay (CBA). Results show that using an CFA as an additional adjuvant can significantly boost Th1 cytokine production (IFN-? and IL-2) without effecting the production of Th2 cytokines (IL-4, IL-5) (FIG. 6). Therefore Th1 responses induced by fluoropeptide vaccination are preferentially boosted by combination with adjuvant during immunization.

(107) Both Subcutaneous and Intradermal Routes of Fluoropeptide Vaccine Administration can Induce Immune Responses

(108) Immunogenicity of the fluoropeptide vaccine (mixture of 8 fluoropeptides as above) was compared using either intradermal or subcutaneous routes of administration in BALB/c mice. 10 days after the immunization, splenocytes were stimulated with individual peptides at 10 ?g/ml and assessed for ex vivo IFN-? production by means of ELISPOT. Results show that both subcutaneous and intradermal routes of fluoropeptide administration are suitable to induce robust antigen-specific responses (FIG. 7).

INCORPORATION BY REFERENCE

(109) The entire disclosure of each of the publications and patent documents referred to herein is incorporated by reference in its entirety for all purposes to the same extent as if each individual publication or patent document were so individually denoted.

EQUIVALENTS

(110) The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.